Cigarette smoking, alcohol intake, and risk of glioma in the NIH-AARP Diet and Health Study

M Z Braganza*,1, P Rajaraman1, Y Park1, P D Inskip1, N D Freedman1, A R Hollenbeck2, A Berrington de González1 and C M Kitahara1

1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Bethesda, MD 20892, USA and 2AARP Research, AARP, 601 E Street NW, Washington, DC 20049, USA

Background: Although cigarette smoking and alcohol drinking increase the risk of several cancers and certain components of cigarette smoke and alcohol can penetrate the blood–brain barrier, it remains unclear whether these exposures influence the risk of glioma.

Methods: We examined the associations between cigarette smoking, alcohol intake, and risk of glioma in the National Institutes of Health-AARP Diet and Health Study, a prospective study of 477 095 US men and women ages 50–71 years at baseline. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using models with age as the time metric and adjusted for sex, race/ethnicity, education, and marital status.

Results: During a median 10.5 person-years of follow-up, 492 men and 212 women were diagnosed with first primary glioma. Among men, current, heavier smoking was associated with a reduced risk of glioma compared with never smoking, but this was based on only nine cases. No associations were observed between smoking behaviours and glioma risk in women. Greater alcohol consumption was associated with a decreased risk of glioma, particularly among men (4 drinks per day vs <1 drink per week: HR = 0.67, 95% CI = 0.51–0.90).

Conclusion: Smoking and alcohol drinking do not appear to increase the risk of glioma.

Apart from a few established risk factors (e.g., exposure to ionising radiation, male sex, non-Hispanic white race/ethnicity) and probable protective factors (e.g., history of allergies), little is known regarding the aetiology of malignant brain tumours, which have a 5-year survival rate of only 34% (Bondy et al, 2008; Dolecek et al, 2012). Cigarette smoking and alcohol drinking are associated with increased risks of several types of cancer, including those of the oral cavity, pharynx, esophagus, larynx, stomach, colon, and rectum (Bagnardi et al, 2001; US Department of Health and Human Services, 2004). In addition, components of cigarette smoke, such as N-nitroso compounds, and alcohol can penetrate the blood–brain barrier (Harper, 2007; Il’yasova et al, 2009). However, it remains unclear whether cigarette smoking and alcohol drinking increase the risk of brain cancer.

Results from observational studies on the relationship between cigarette smoking, alcohol intake, and risk of glioma, the most common brain malignancy, have been inconsistent, with results differing largely by study design (Mandelzweig et al, 2009; Galeone et al, 2013). Although prospective studies avoid potential biases associated with differential selection and recall between cases and controls and the reliance on proxy respondents, to date, few prospective studies have examined cigarette smoking and/or alcohol intake in relation to glioma risk (Mills et al, 1989; Efird et al, 2004; Silvera et al, 2006; Holick et al, 2007; Benson et al, 2008; Baglietto et al, 2011), and some were relatively small (<100 cases; Mills et al, 1989; Baglietto et al, 2011). Only two prospective studies have investigated risk in relation to beer, wine, and liquor intake with conflicting results; thus, it remains unclear whether
consumption of particular types of alcohol influence glioma risk (Eifler et al, 2004; Baglietto et al, 2011).

We investigated the relationship between cigarette smoking, alcohol intake, and glioma risk in the National Institutes of Health-AARP (formally known as the American Association of Retired Persons, NIH-AARP) Diet and Health Study, a large prospective cohort study with detailed information on cigarette smoking behaviours (smoking status, intensity, and years since quitting) and alcohol drinking (type and level of intake) for more than 450,000 men and women.

MATERIAL AND METHODS

Study population. Data collection for the NIH-AARP study was initiated between 1995 and 1996 when questionnaires were mailed to AARP members between the ages of 50 and 71 years who resided in the states of California, Florida, Louisiana, Pennsylvania, New Jersey, and North Carolina and the metropolitan areas of Atlanta, Georgia, and Detroit, Michigan (Schatzkin et al, 2001). The self-administered baseline questionnaire ascertained information on demographics, diet, family history of cancer, prior medical conditions, reproductive and hormonal factors, cigarette smoking and alcohol intake, and other lifestyle characteristics (Schatzkin et al, 2001). Cancer outcomes were ascertained through linkage to state cancer registries (Schatzkin et al, 2001). The matching of study participants to cancer registries identified approximately 90% of cancer cases (Michaud et al, 2005). All participants provided informed written consent, and the study was approved by the Special Studies Institutional Review Board of the US National Cancer Institute.

Of the 566,398 individuals who satisfactorily completed the baseline questionnaire, we excluded proxy respondents (n = 15,760), participants with self-reported cancer (except for non-melanoma skin cancer; n = 51,223) or end-stage renal disease (n = 997) at baseline, any cancer cases that were identified only through death records (n = 2143), and respondents with missing information on cigarette smoking (n = 19,180). Our final study population consisted of 477,095 individuals: 283,979 men and 193,116 women.

Ascertainment of exposure and outcome and follow-up. Smoking was classified according to cigarette smoking status (never, former, current), smoking intensity (1–10, 11–20, 21–30, >30 cigarettes per day), years since quitting (among former cigarette smokers: >0–4, 5–9, 10+ years), and regular use of pipes and cigars for a year or longer (ever vs never). The food frequency questionnaire, an earlier version of the National Cancer Institute’s Diet History Questionnaire, captured portion sizes (beer: <12-ounce can, 1 to 2 12-ounce cans, >2 12-ounce cans; wine: <4 ounces, 4–8 ounces, >8 ounces; liquor and mixed drinks: <1 shot, 1–2 shots, >2 shots) and frequency of consumption (never to ≥6 times per day) of beer during the summer, beer during the rest of the year, wine and wine coolers, and liquor and mixed drinks over the previous 12 months. Alcohol intake was standardised using the US Department of Agriculture MyPyramid Servings database, with one alcoholic drink corresponding to 12 fluid ounces of beer (12.96 g of ethanol), 5 fluid ounces of wine (13.72 g of ethanol), and 1.5 fluid ounces of 80-proof distilled spirits (13.93 g of ethanol). We examined glioma risk according to the frequency of intake (none, <1 drink per week, 1–6 drinks per week, 1–2 drinks per day, >2 drinks per day) for total alcohol, beer, wine, and liquor, separately. We also evaluated the risks of glioma associated with pattern of alcohol intake. Individuals were classified as primarily beer, primarily wine, or primarily liquor drinkers if ≥75% of their alcohol intake consisted of beer, wine, or liquor, respectively. All other individuals were classified as either mixed drinkers (alcohol drinkers with no apparent alcoholic beverage preference) or nondrinkers.

RESULTS

Statistical analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) for glioma were calculated using Cox proportional hazard models, adjusted for sex, race/ethnicity, education, and marital status with attained age as the underlying time metric. We additionally investigated risk by sex because incidence of glioma is notably higher in men, and it remains unknown whether these sex differences are due to physiological differences or differences in lifestyle-related or environmental exposures. Missing values were modelled using a separate indicator variable. Participants who drank <1 drink per week were the reference group for the models examining total alcohol, beer, wine, and liquor consumption because nondrinkers could include former drinkers who stopped drinking for reasons such as poor health. We did not observe evidence of a deviation from proportional hazards. Tests for linear trend were conducted by modelling categorical variables as continuous and Wald tests were conducted. We also investigated the joint association between total alcohol intake (≤1 drink per day, >1 drinks per day) and smoking status (never, former, current) on the risk of glioma. Multiplicative interactions were tested by comparing the fit of a model including a cross-product term to a model not including this term using the likelihood ratio test. Where possible, we examined smoking and alcohol in relation to histological subtypes of glioma. Statistical analyses were performed using Stata 11.2 (Stata Corporation, College Station, TX, USA).

The majority of study participants were former or current smokers, and about half consumed >0 and <1 alcoholic drink per day (Table 1). Current smokers were more likely to be high school graduates and drink primarily beer or liquor relative to never smokers. Compared with nondrinkers, participants who consumed >2 drinks per day were more likely to be male, non-Hispanic white, college graduates, former smokers, and pipe and/or cigar smokers.

During a median 10.5 person-years of follow-up, 492 men and 212 women were diagnosed with glioma. The most common histological subtypes were glioblastoma (542 cases; 77%), astrocytoma (93 cases; 13%), and oligodendroglioma (36 cases; 5%). Compared with never smoking, former (HR = 0.90, 95% CI = 0.75–1.09) and current (HR = 0.67, 95% CI = 0.47–0.97) cigarette smoking were associated with a decreased risk of glioma in men only (Table 2). Among men, current, heavier (>20 cigarettes per day) smoking was associated with a reduced risk of glioma compared with never smoking (HR = 0.40, 95% CI = 0.21–0.79); however, this association was based on only nine exposed cases. Current smoking for ≤20 cigarettes a day vs never smoking was not associated with risk in men (HR = 0.87, 95% CI = 0.58–1.32).

Men who quit smoking <5 years before baseline had a non-significant reduced risk of glioma (HR = 0.73, 95% CI = 0.46–1.14) relative to never smokers, but no clear trend with greater number of years since quitting was observed. No clear
Table 1. Baseline characteristics of men and women in the NIH-AARP Diet and Health Study according to smoking status and alcohol intake

| Smoking status | Alcohol intake | 0 | 1 Drink per day | 1–2 Drinks per day | >2 Drinks per day |
|----------------|----------------|---|-----------------|-------------------|-------------------|
|                | Never          | Former | Current | None | <1 Drink per day | 1–2 Drinks per day | >2 Drinks per day |
| Study participants | 174 244 | 243 407 | 59 444 | 115 889 | 251 635 | 55 776 | 53 795 |
| Age at baseline, years (median) | 62.3 | 63.0 | 61.0 | 63.0 | 62.2 | 63.1 | 62.5 |
| Sex (%) | | | | | | | |
| Male | 49 | 69 | 52 | 51 | 56 | 72 | 82 |
| Female | 51 | 31 | 48 | 49 | 44 | 28 | 18 |
| Race/ethnicity (%) | | | | | | | |
| Non-Hispanic white | 90 | 92 | 91 | 88 | 92 | 95 | 95 |
| Non-Hispanic black | 4 | 3 | 5 | 6 | 3 | 2 | 2 |
| Hispanic/other | 5 | 3 | 3 | 4 | 4 | 2 | 2 |
| Missing | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Education (%) | | | | | | | |
| <High school | 4 | 6 | 9 | 10 | 5 | 4 | 5 |
| High school graduate | 49 | 53 | 62 | 57 | 53 | 44 | 49 |
| College graduate | 44 | 38 | 29 | 39 | 39 | 49 | 44 |
| Missing | 3 | 3 | 3 | 4 | 3 | 2 | 2 |
| Body mass index (%) | | | | | | | |
| <25 kg m⁻² | 37 | 30 | 44 | 32 | 35 | 40 | 34 |
| 25–29.9 kg m⁻² | 39 | 44 | 37 | 39 | 41 | 44 | 46 |
| ≥30 kg m⁻² | 21 | 23 | 16 | 26 | 22 | 15 | 18 |
| Missing | 3 | 2 | 3 | 2 | 3 | 2 | 2 |
| Family history of cancer (%) | | | | | | | |
| No | 47 | 46 | 47 | 47 | 46 | 46 | 47 |
| Yes | 49 | 49 | 48 | 48 | 49 | 49 | 48 |
| Missing | 4 | 4 | 5 | 5 | 4 | 4 | 5 |
| Drinking pattern* (%) | | | | | | | |
| Primarily beer | 11 | 17 | 20 | 0 | 13 | 17 | 27 |
| Primarily wine | 28 | 21 | 14 | 0 | 24 | 25 | 13 |
| Primarily liquor | 11 | 16 | 27 | 0 | 11 | 25 | 31 |
| Mixed | 49 | 46 | 38 | 0 | 52 | 33 | 29 |
| Cigarette smoking status (%) | | | | | | | |
| Never smoked | 100 | 0 | 0 | 45 | 38 | 27 | 19 |
| Former smoker | 0 | 100 | 0 | 44 | 50 | 60 | 62 |
| Current smoker | 0 | 0 | 100 | 11 | 12 | 13 | 20 |
| Cigarette smoking intensity (%) | | | | | | | |
| Never smoked | 100 | 0 | 0 | 45 | 38 | 27 | 19 |
| <20 Cigarettes per day | 0 | 56 | 65 | 31 | 38 | 42 | 38 |
| >20 Cigarettes per day | 0 | 44 | 35 | 24 | 23 | 31 | 43 |
| Cigar/pipe smokingd (%) | | | | | | | |
| Never smoked | 86 | 0 | 0 | 40 | 33 | 22 | 14 |
| Cigarettes only | 0 | 75 | 86 | 44 | 48 | 53 | 57 |
| Cigars only | 2 | 5 | 2 | 3 | 3 | 5 | 7 |
| Pipes only | 3 | 9 | 5 | 4 | 6 | 9 | 9 |
| Both cigars and pipes | 4 | 11 | 5 | 5 | 7 | 10 | 12 |
| Missing | 5 | 1 | 2 | 3 | 3 | 2 | 2 |

* Excludes participants reporting no intake of total alcohol.
** >75% of total alcohol intake is of that particular type of alcohol.
*** >75% of total alcohol intake is not of one particular alcohol type.
**** Ever regular use of pipes or cigars for at least one year.
associations were observed for smoking status, intensity, and time since quitting in women. Cigar and pipe smoking were not clearly associated with glioma risk in men or women. The magnitude of the HRs in the models of smoking and glioma risk did not change appreciably after additional adjustment for total alcohol intake (results not shown).

Overall, we observed a reduced risk of glioma with consumption of >2 drinks per day compared with <1 drink per week (Table 3). Among men, the inverse association appeared to be stronger for beer (HR = 0.56, 95% CI = 0.33–0.93) compared with wine (HR = 0.98, 95% CI = 0.53–1.81) or liquor (HR = 0.68, 95% CI = 0.43–1.09) consumption. The inverse association with beer consumption was less clear in women (>1 drink per week vs <1 drink per week: HR = 0.66, 95% CI = 0.33–1.34), which may reflect the small number of cases (n = 9) in women reporting ≥1 drink per week. Men who were primarily beer (HR = 0.77, 95% CI = 0.59–1.02) or liquor (HR = 0.70, 95% CI = 0.51–0.95) drinkers had a reduced risk of glioma compared with alcohol drinkers with no alcoholic beverage preference. Women who were primarily wine (HR = 1.50, 95% CI = 1.03–2.20) or liquor (HR = 1.79, 95% CI = 1.15–2.79) drinkers had a significantly increased risk of glioma compared with alcohol drinkers with no alcoholic beverage preference. A possible explanation for the increased risks associated with a preference for wine or liquor is the disproportionately large number of heavier beer drinkers among women in the mixed category (reference group). Adjusting for cigarette smoking status and intensity in the total alcohol, beer, wine, and liquor models or mutually adjusting for the other alcohol types in the beer, wine, and liquor models did not change the HRs appreciably (results not shown).

When we restricted the outcome to glioblastoma, results were similar (Supplementary Tables 1 and 2). No associations were observed between ever smoking and risk of astrocytoma for men (HR = 0.86, 95% CI = 0.51–1.45) or women (HR = 1.13, 95% CI = 0.53–2.41). HRs per drink per day for astrocytoma in men and women, respectively, were 0.88 (95% CI = 0.74–1.06) and 1.02 (95% CI = 0.82–1.28). Ever smoking was not significantly associated with risk of

### Table 2. HRs and 95% CIs for glioma according to smoking status and intensity

| Cigarette smoking status | Total (n = 477 095) | Men (n = 283 979) | Women (n = 193 116) |
|--------------------------|--------------------|-------------------|--------------------|
|                          | Cases  | HR (95% CI)a | Cases  | HR (95% CI)b | Cases  | HR (95% CI)b |
| Never                    | 265    | 1.00 (Reference) | 169    | 1.00 (Reference) | 96    | 1.00 (Reference) |
| Former                   | 374    | 0.95 (0.81, 1.12) | 288    | 0.90 (0.75, 1.09) | 86    | 1.08 (0.81, 1.44) |
| Current                  | 65     | 0.83 (0.63, 1.09) | 35     | 0.67 (0.47, 0.97) | 30    | 1.14 (0.75, 1.73) |

### Cigarette smoking intensity

| Cigarette smoking status | Total (n = 477 095) | Men (n = 283 979) | Women (n = 193 116) |
|--------------------------|--------------------|-------------------|--------------------|
|                          | Cases  | HR (95% CI)a | Cases  | HR (95% CI)b | Cases  | HR (95% CI)b |
| Never                    | 265    | 1.00 (Reference) | 169    | 1.00 (Reference) | 96    | 1.00 (Reference) |
| 1–10 Cigarettes per day  | 128    | 1.13 (0.91, 1.39) | 78     | 1.06 (0.81, 1.38) | 50    | 1.28 (0.91, 1.80) |
| 11–20 Cigarettes per day | 127    | 0.82 (0.66, 1.02) | 95     | 0.80 (0.62, 1.03) | 32    | 0.88 (0.59, 1.32) |
| 21–30 Cigarettes per day | 80     | 0.83 (0.64, 1.07) | 61     | 0.76 (0.56, 1.02) | 19    | 1.11 (0.68, 1.82) |
| >30 Cigarettes per day   | 104    | 0.95 (0.75, 1.20) | 89     | 0.91 (0.70, 1.18) | 15    | 1.09 (0.63, 1.88) |
| P-trend                  |         | 0.31             |         | 0.43             |         | 0.49             |

### Time since quitting

| Cigarette smoking status | Total (n = 477 095) | Men (n = 283 979) | Women (n = 193 116) |
|--------------------------|--------------------|-------------------|--------------------|
|                          | Cases  | HR (95% CI)a | Cases  | HR (95% CI)b | Cases  | HR (95% CI)b |
| Never                    | 265    | 1.00 (Reference) | 169    | 1.00 (Reference) | 96    | 1.00 (Reference) |
| <10 Years                | 290    | 0.96 (0.81, 1.14) | 231    | 0.92 (0.75, 1.12) | 59    | 1.00 (Reference) |
| 5–9 Years                | 46     | 0.90 (0.65, 1.23) | 36     | 0.94 (0.65, 1.35) | 10    | 0.75 (0.39, 1.44) |
| <5 Years                 | 38     | 0.94 (0.67, 1.32) | 21     | 0.73 (0.46, 1.14) | 17    | 1.44 (0.86, 2.42) |
| P-trend                  |         | 0.81             |         | 0.47             |         | 0.53             |

### Cigar/pipe smoking

| Cigarette smoking status | Total (n = 477 095) | Men (n = 283 979) | Women (n = 193 116) |
|--------------------------|--------------------|-------------------|--------------------|
|                          | Cases  | HR (95% CI)a | Cases  | HR (95% CI)b | Cases  | HR (95% CI)b |
| Never                    | 224    | 1.00 (Reference) | 134    | 1.00 (Reference) | 90    | 1.00 (Reference) |
| Cigarettes only          | 323    | 0.94 (0.79, 1.11) | 209    | 0.87 (0.70, 1.08) | 114   | 1.08 (0.82, 1.43) |
| Cigars only              | 31     | 0.98 (0.67, 1.43) | 31     | 0.95 (0.64, 1.41) | 0     | NA              |
| Pipes only               | 57     | 1.06 (0.79, 1.44) | 57     | 1.02 (0.75, 1.39) | 0     | NA              |
| Both cigars and pipes   | 54     | 0.82 (0.60, 1.12) | 54     | 0.79 (0.58, 1.09) | 0     | NA              |

Abbreviations: CI = confidence interval; HR = hazard ratio; NA = not applicable.

aAdjusted for sex, education, marital status, and race/ethnicity.
bAdjusted for education, marital status, and race/ethnicity.

P-trend calculated by modelling the categorical variable as continuous and excluding never smokers.

P-trend calculated by modelling the categorical variable as continuous and excluding never and current smokers.

*Ever regular use of pipes or cigars for at least 1 year.
Among women (HR = 1.06, 95% CI = 1.02–1.11) but no increased risk among men (HR = 1.04, 95% CI = 0.32–3.45). For each additional alcoholic drink per day, there was a slightly elevated risk of oligodendroglioma among men (HR = 1.06, 95% CI = 1.02–1.11) but no increased risk among women (HR = 1.02, 95% CI = 0.71–1.47).

In joint models, current smoking and >1 drink per day was associated with a 63% reduction in risk of glioma in men compared with never smoking and ≤1 drink per day (HR = 0.37, 95% CI = 0.17–0.79), and the interaction between smoking status and total alcohol intake appeared to be supra-multiplicative (P-interaction = 0.01). The HRs observed for never smoking among men who consumed >1 drink per day and current smoking among men who consumed ≤1 drink per day were 1.15 (95% CI = 0.81–1.64) and 0.90 (95% CI = 0.60–1.36), respectively.

Our results did not change materially after excluding the first two years of follow-up time, excluding participants who reported being in poor health at baseline, or after including additional covariates from previous studies of glioma in this cohort: family history of cancer, fruit intake (Dubrow et al, 2010), caffeine consumption (Dubrow et al, 2012), adult height (Moore et al, 2009), and age at menarche (Kabat et al, 2011). We did not observe interactions between sex and smoking status (P-interaction = 0.30) or alcohol intake (P-interaction = 0.61).

### Table 3. HRs and 95% CIs for glioma according to alcohol intake

| Alcohol | Cases | HR (95% CI) | Cases | HR (95% CI) | Cases | HR (95% CI) |
|---------|-------|------------|-------|------------|-------|------------|
| None    | 159   | 0.93 (0.75, 1.15) | 94    | 0.87 (0.65, 1.14) | 65    | 1.03 (0.74, 1.43) |
| <1 Drink per week | 193 | 1.00 (Reference) | 112 | 1.00 (Reference) | 81 | 1.00 (Reference) |
| 1-6 Drinks per week | 193 | 0.92 (0.75, 1.13) | 155 | 0.96 (0.75, 1.23) | 38 | 0.79 (0.54, 1.16) |
| 1-2 Drinks per day | 95 | 0.96 (0.75, 1.23) | 75 | 0.92 (0.69, 1.24) | 28 | 0.96 (0.63, 1.48) |
| >2 Drinks per day | 64 | 0.67 (0.51, 0.90) | 56 | 0.65 (0.47, 0.90) | 0.02 | 0.45 |
| P-trend | 0.18 | 0.02 | 0.96 (0.92, 0.99) | 398 | 0.96 (0.92, 0.99) | 147 | 0.92 (0.78, 1.09) |
| Per drink per day* | 545 | 0.96 (0.92, 0.99) | 398 | 0.96 (0.92, 0.99) | 147 | 0.92 (0.78, 1.09) |
| Beer | <1 Drink per week | 257 | 1.00 (Reference) | 196 | 1.00 (Reference) | 61 | 1.00 (Reference) |
| 1-6 Drinks per week | 119 | 0.95 (0.76, 1.18) | 111 | 0.96 (0.76, 1.21) | 9 | 0.66 (0.33, 1.34) |
| 1-2 Drinks per day | 17 | 0.67 (0.41, 1.09) | 16 | 0.66 (0.40, 1.10) | 0.03 | 0.27 |
| >2 Drinks per day | 16 | 0.54 (0.33, 0.90) | 16 | 0.56 (0.33, 0.93) | 0.01 | 0.40 |
| P-trend | 0.01 | 0.03 | 0.96 (0.91, 1.01) | 339 | 0.96 (0.91, 1.02) | 70 | 0.75 (0.37, 1.52) |
| Per drink per day* | 409 | 0.96 (0.91, 1.01) | 339 | 0.96 (0.91, 1.02) | 70 | 0.75 (0.37, 1.52) |
| Wine | <1 Drink per week | 253 | 1.00 (Reference) | 180 | 1.00 (Reference) | 73 | 1.00 (Reference) |
| 1-6 Drinks per week | 128 | 1.09 (0.88, 1.34) | 94 | 1.02 (0.80, 1.31) | 34 | 1.24 (0.83, 1.87) |
| 1-2 Drinks per day | 36 | 1.02 (0.72, 1.45) | 27 | 0.96 (0.64, 1.44) | 12 | 1.15 (0.62, 2.12) |
| >2 Drinks per day | 14 | 1.01 (0.59, 1.74) | 11 | 0.98 (0.53, 1.81) | 0.89 | 0.40 |
| P-trend | 0.78 | 0.03 | 0.96 (0.84, 1.12) | 312 | 0.95 (0.81, 1.13) | 119 | 1.02 (0.76, 1.38) |
| Per drink per day* | 431 | 0.97 (0.84, 1.12) | 312 | 0.95 (0.81, 1.13) | 119 | 1.02 (0.76, 1.38) |
| Liquor | <1 Drink per week | 239 | 1.00 (Reference) | 166 | 1.00 (Reference) | 73 | 1.00 (Reference) |
| 1-6 Drinks per week | 89 | 1.19 (0.93, 1.52) | 74 | 1.20 (0.91, 1.57) | 15 | 1.11 (0.64, 1.94) |
| 1-2 Drinks per day | 35 | 0.86 (0.60, 1.23) | 27 | 0.80 (0.53, 1.20) | 11 | 0.96 (0.51, 1.80) |
| >2 Drinks per day | 23 | 0.70 (0.46, 1.08) | 20 | 0.68 (0.43, 1.09) | 0.25 | 0.96 |
| P-trend | 0.30 | 0.02 | 0.94 (0.88, 1.01) | 287 | 0.94 (0.88, 1.01) | 99 | 0.93 (0.74, 1.16) |
| Per drink per day* | 386 | 0.94 (0.88, 1.01) | 287 | 0.94 (0.88, 1.01) | 99 | 0.93 (0.74, 1.16) |
| Drinking pattern | Mixed | 257 | 1.00 (Reference) | 208 | 1.00 (Reference) | 49 | 1.00 (Reference) |
| Primarily beer | 76 | 0.83 (0.64, 1.07) | 69 | 0.77 (0.59, 1.02) | 7 | 1.05 (0.47, 2.32) |
| Primarily wine | 132 | 1.12 (0.91, 1.38) | 74 | 1.02 (0.78, 1.33) | 58 | 1.50 (1.03, 2.20) |
| Primarily liquor | 80 | 0.93 (0.72, 1.19) | 47 | 0.70 (0.51, 0.95) | 33 | 1.79 (1.15, 2.79) |

**Abbreviations:** CI = confidence interval; HR = hazard ratio.

- Adjusted for sex, education, marital status, and race/ethnicity.
- Adjusted for education, marital status, and race/ethnicity.
- Reference group is <1 drink per week with none modelled as a separate category.
- Reference group is alcohol drinkers with no apparent beverage preference.
- Excludes nondrinkers of that particular alcoholic beverage.
- Reference group is <1 drink per week for that particular alcoholic beverage with none modelled as a separate category (results not shown).
- Reference group is alcohol drinkers with no apparent beverage preference (≥75% of total alcohol intake is not of one particular alcohol type) with none modelled as a separate category (results not shown).
- Reference group is <1 drink per day for that particular alcoholic beverage with nondrinkers of that beverage modelled as a separate category.

Oligodendroglioma in men (HR = 1.44, 95% CI = 0.57–3.65) or women (HR = 1.04, 95% CI = 0.32–3.45). For each additional alcoholic drink per day, there was a slightly elevated risk of oligodendroglioma among men (HR = 1.06, 95% CI = 1.02–1.11) but no increased risk among women (HR = 1.02, 95% CI = 0.71–1.47).
Education level did not modify the associations between smoking status \( (P\text{-interaction} = 0.93) \) or alcohol intake \( (P\text{-interaction} = 0.52) \) and the risk of glioma (Supplementary Table 3).

**DISCUSSION**

In this large prospective study, heavy, current cigarette smoking was associated with a reduced risk of glioma in men; however, this finding was based on only nine exposed cases. Cigarette smoking was not associated with glioma risk in women. Cigar and pipe smoking were not associated with risk of glioma in men or women. Greater alcohol, particularly beer, consumption was associated with a reduced risk of glioma, most clearly among men. Wine and liquor consumption were not associated with glioma risk in a dose-dependent manner in either men or women.

Because certain components of cigarette smoke (International Agency for Research on Cancer, 2004) and alcohol (International Agency for Research on Cancer, 2010) are established carcinogens, we expected to observe, if anything, positive associations between cigarette smoking, alcohol drinking, and glioma risk. Of the few prospective studies that separately examined the association between smoking and brain cancer risk in men, the results have generally been null. (McLaughlin et al., 1995; Efird et al., 2004; Holick et al., 2007) Therefore, the inverse association that we observed for current, heavier cigarette smoking and glioma risk in men may be due to chance or residual confounding by other factors, such as socioeconomic status. Current cigarette smoking has been associated with lower education, and the incidence of glioma has been shown to increase with social class (Preston-Martin et al., 2006), particularly among men, and we found similar patterns in the current study. Similar to our results for women, observational studies have generally found no association between cigarette smoking behaviours and risk of glioma in women (Hurley et al., 1996; Blowers et al., 1997; Lee et al., 1997; Zheng et al., 2001; Holick et al., 2007; Benson et al., 2008); however, there were some exceptions, including two prospective studies having observed an increased risk with greater number of cigarettes smoked per day (Efird et al., 2004; Silvera et al., 2006).

The clear inverse association between alcohol drinking and glioma risk in this study, although unexpected, is based on a large number of cases across a wide distribution of intake and concurs with the results from several previous studies on this topic. A meta-analysis of case–control studies, including the largest case–control study published on this topic, reported a significantly reduced risk of glioma for ever vs never drinking in men and women combined (Ruder et al., 2006; Galeone et al., 2013). Similar to results from our study, some (Preston-Martin et al., 1989; Hurley et al., 1996), but not all (Hu et al., 1998), case–control studies support a reduced risk of glioma with beer consumption in men. Results from the few prospective studies on this topic are largely inconsistent, which may reflect small numbers of cases, relatively narrow ranges of alcohol intake, and the inability to separate total alcohol from beer, wine, and liquor (Mills et al., 1989; Efird et al., 2004; Benson et al., 2008; Kim et al., 2010; Baglietto et al., 2011). As in observational studies, confounding by unknown factors is a possibility, and in particular, residual confounding by socioeconomic status is a potential concern in the current study. Beer, wine, and liquor intake have each been associated with socioeconomic indicators (McCann et al., 2003), and glioma incidence appears to increase with social class (Preston-Martin et al., 2006). Although we did not observe dose–response associations for wine or liquor intake or differences in our results for total and specific alcohol types according to education level, we acknowledge lacking information on income, access to health care, and other indicators of socioeconomic status, and residual confounding by socioeconomic status is possible. Although the International Agency for Research on Cancer has classified ethanol as a human carcinogen (International Agency for Research on Cancer, 2010), other components of beer may explain its potentially protective effect on glioma (Arranz et al., 2012). Xanthohumol, a polyphenolic compound present in beer, has exhibited anticancer properties, including inducing cell-programmed death in malignant glioma cells in a concentration-dependent manner (Festa et al., 2011; Zajc et al., 2012). These alternative mechanisms may explain why alcohol drinking has also been associated with reduced risks of other malignancies, including renal cell (Allen et al., 2009) and thyroid (Allen et al., 2009; Kitahara et al., 2012) cancers.

To our knowledge, this is the largest prospective cohort study among men and one of the largest among women on cigarette smoking and alcohol intake in relation to risk of glioma. The prospective design ensured that self-reported information on smoking and alcohol intake was not influenced by diagnosis of glioma. In addition, the relatively large number of glioma cases allowed for a precise investigation of risk by sex and across a relatively wide range of total alcohol, beer, wine, and liquor intakes. We were able to examine associations of smoking and alcohol intake in relation to histological sub-types of glioma, which are thought to differ aetiologically (Ohgaki and Kleihues, 2005).

Although a wide range of smoking-related behaviours were ascertained in this study, age at smoking initiation and total number of years smoked were not captured in the baseline questionnaire. In addition, we were unable to account for changes in smoking behaviours during follow-up, which may have attenuated our results. Baseline assessment of alcohol intake was based on consumption over the previous 12 months, so we could not examine associations for patterns in alcohol consumption throughout adulthood. To take into account the possibility that some participants’ alcohol habits may have changed as a result of preclinical disease at baseline, we excluded the first 2 years of follow-up, but our results did not change. There may be residual confounding by other factors that were not ascertained in this study or that were accounted for in the analysis but were measured with error.

Cigarette smoking and alcohol drinking were not associated with an increased risk of glioma in this study. More prospective studies and pooled analyses, particularly ones having a wide range of consumption of alcohol, beer, wine, and liquor, as well as detailed information on drinking patterns throughout adulthood, are needed to provide further insight into the possible inverse association between alcohol drinking and glioma risk.

**ACKNOWLEDGEMENTS**

This work was supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**REFERENCES**

Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, Green J (2009) Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 101(5): 296–305.

Arranz S, Chiva-Blanch G, Valderas-Martinez P, Medina-Remon A, Lamuela-Raventos RM, Estruch R (2012) Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. Nutrients 4(7): 759–781.
Kim MK, Ko MJ, Han JT (2010) Alcohol consumption and mortality from all-cause and cancers among 1.34 million Koreans: the results from the Korea national health insurance corporation’s health examinee cohort in 2000. Cancer Causes Control 21(12): 2295–2302.

Kitahara CM, Linet MS, Beane Freeman LE, Check DP, Church TR, Park Y, Purdue MP, Schairer C, Berrington de Gonzalez A (2012) Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control 23(10): 1615–1624.

Lee H, Wrensch M, M ö re K (1997) Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 8(1): 13–24.

Mandelweiz L, Novikov I, Sadezki S (2009) Smoking and risk of glioma: a meta-analysis. Cancer Causes Control 20(10): 1927–1938.

McCann SE, Sepkos, C, Freudenheim JL, Mutti P, Russell M, Nochajski TH, Ram M, Hovey K, Trevisan M (2003) Alcoholic beverage preference and characteristics of drinkers and nondrinkers in western New York (United States). Nutr Metab Cardiovasc Dis 13(1): 2–11.

McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni Jr JF (1985) Smoking and cancer mortality among U.S. veterans: a 26-year follow-up. Int J Cancer 60(2): 190–193.

Michaud D, Midhuthe D, Hermanssen S, Leitzmann MF, Arland LC, Kipnis V, Schatzkin A (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manag 32(2): 70–75.

Mills PK, Preston-Martin S, Avensges JF, Beeson WL, Phillips RL, Fraser GE (1989) Risk factors for tumors of the brain and cranial meninges in Seventh-Day Adventists. Neuroepidemiology 8(5): 265–275.

Moore SC, Rajaraman P, Dubrow R, Drefsky AS, Koebnick C, Hollenbeck A, Schatzkin A, Leitzmann MF (2009) Height, body mass index, and physical activity in relation to glioma risk. Cancer Res 69(21): 8349–8355.

Ohaghi H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathologica 109(1): 93–108.

Preston-Martin S, Mack W, Henderson BE (1989) Risk factors for gliomas and meningiomas in males in Los Angeles County. Cancer Res 49(21): 6137–6143.

Preston-Martin S, Munir R, Chakrabarti I (2006) Nervous System. In: Cancer Epidemiology and Prevention, Schottenfeld D, Fraumeni JF (eds). 3rd edn., Chapter 62, pp xxvii–1392 (Oxford University Press: Oxford; New York.

Rudder AM, Waters MA, Carroon T, Butler MA, Davis-King KE, Calvert GM, Schulte PA, Ward EM, Connally LB, Liu J, Wall D, Zvikovich Z, Heineman EF, Mandel JS, Morton RF, Reding DJ, Rosenman KD (2006) The Upper Midwest Health Study: A case-control study of primary intracranial gliomas in farm and rural residents. J Agic Safety Health 12(4): 255–274.

Schwartzbaum JA, Subar AF, Thompson FE, Harland LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC, Midhuthe D, Kipnis V (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiology 114(12): 911–1125.

Silversa S, Miller AB, Rohan TE (2006) Cigarette smoking and risk of glioma: a prospective cohort study. Int J Cancer 118(7): 1848–1851.

US Department of Health and Human Services (2004) The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA.

Zajc I, Filipic M, Lah TT (2012) Xanthohumol induces different cytotoxicity and apoptotic pathways in malignant and normal astrocytes. Phytother Res 26(11): 1709–1713.

Zhang TQ, Cantor KP, Zhang YW, Chiu BHC, Lynch CF (2001) Risk of brain glioma not associated with cigarette smoking or use of other tobacco products in Iowa. Cancer Epidemiol Biomark 10(4): 413–414.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)